**General description**

Ifosfamide is a nitrogen mustard alkylating agent used in treatment protocols for bone and soft tissue sarcomas, and testicular and ovarian cancers.

<table>
<thead>
<tr>
<th>INN</th>
<th>Ifosfamide</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATC codes</td>
<td>L01AA06</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
<tr>
<td>EML status history</td>
<td>First added in 2009 (TRS 958) for Rhabdomyosarcoma primary site Added in 2009 (TRS 958) for Germ cell tumour of testis Added in 2009 (TRS 958) for Ewing sarcoma of bone and articular cartilage of unspecified sites Added in 2009 (TRS 958) for Osteosarcoma of bone and articular cartilage of unspecified sites Added in 2009 (TRS 958) for Other specified malignant neoplasms of the ovary Added in 2009 (TRS 958) for Unspecified malignant neoplasms of ill-defined or unspecified sites Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
</tbody>
</table>

**Recommendations**

**Section**

Cytotoxic medicines

- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection
- Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

**Indications**

- Osteosarcoma of bone and articular cartilage of unspecified sites
- Other specified malignant neoplasms of the ovary
- Germ cell tumour of testis
- Rhabdomyosarcoma primary site
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Unspecified malignant neoplasms of ill-defined or unspecified sites